Fig. 5From: Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patientsImpact of ToxNav on adverse events compared with No-ToxNavBack to article page